Prevalence of Eating Disorders Among Adults With Irritable Bowel Syndrome: A Cross-Sectional Study
Abstract
GOAL
To investigate the prevalence of eating disorder (ED) symptoms among Mexican adults with irritable bowel syndrome (IBS).
BACKGROUND
The relationship between IBS and EDs is complex, yet understudied, particularly in Latin America.
METHODS
In this cross-sectional study, 369 Mexican adults (18 to 69 y), comprising 133 IBS patients and 236 healthy controls (HCs), were evaluated using the Rome IV criteria, The Spanish version of the Eating Disorder Examination Questionnaire (S-EDE-Q), the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) and the Hospital Anxiety and Depression Scale (HADS). Statistical analysis included the Student t test or the Wilcoxon Rank-sum test for group comparisons, the Kruskal-Wallis test for multiple comparisons, and logistic regression, with a significance threshold set at a P-value of <0.05.
RESULTS
IBS individuals were at an increased risk for clinically significant S-EDE-Q when compared with HCs (12.8% vs. 3.8%, odds ratio OR 3.6, 95% CI: 1.5-8.5; P=0.001), especially among younger individuals. IBS individuals displayed a higher risk for dietary restraint and heightened concerns about eating, body shape, and weight. In addition, binge-eating episodes occurred more frequently within the IBS group. Notably, there were no significant differences in body mass index between individuals with clinically significant S-EDE-Q and those with normal scores. IBS individuals with severe symptoms had higher S-EDE-Q scores; furthermore, those with IBS…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 369 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.